Without an IPO, Rib-X Raises $67.5 Million In Venture Funding
Rib-X will use the venture infusion to try to replicate Phase IIb data that indicated superiority to vancomycin for its broad-spectrum fluoroquinolone antibiotic.
Rib-X will use the venture infusion to try to replicate Phase IIb data that indicated superiority to vancomycin for its broad-spectrum fluoroquinolone antibiotic.